RLA-23174

N/A

Report date: 2025/06/05 20:00:13
NME

Base Information

Drug NameRLA-23174
Drug Alias NameRLA-23174RLA23174
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHomeodomain Interacting Protein Kinase 2 inhibitors
TargetsHomeodomain Interacting Protein Kinase 2
Therapy Area/IndicationsRenal fibrosisRenal Insufficiency, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesYL-Pharma
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesYL-Pharma
Inactive CompaniesN/A
Active IndicationsRenal fibrosisRenal Insufficiency, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A